Q-omics provides the consensus-scored POLR2J profile across patient tissues and cancer cell-line models. POLR2J expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, POLR2J is differentially expressed in 14, with the highest sampling consensus in KIRC. Additionally, POLR2J RNA expression shows 19,121 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRC, and THYM as cancer lineages where POLR2J shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for POLR2J — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes POLR2J survival associations across molecular data types. POLR2J RNA expression shows survival associations in the most cancer types (24), followed by mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible POLR2J RNA expression–survival associations across cancer types. High POLR2J expression shows unfavorable associations in KIRC, UVM, KICH, ACC, UCS and LGG. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for POLR2J RNA expression.
This table summarizes POLR2J tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 2. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for POLR2J. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. POLR2J shows higher tumor expression in KIRC, KIRP, COAD, LIHC, HNSC and LUSC. The KIRC box plot shows higher POLR2J RNA expression in tumor versus normal tissue (log2 FC = +0.854, t-test p < 0.001).
This table shows molecular features associated with POLR2J in patient tissues and cancer cell lines. In patient samples, POLR2J shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, POLR2J RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in CNS.
